Hillsdale Investment Management Inc. Immunovant, Inc. Transaction History

Hillsdale Investment Management Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$30.27 - $43.79 $248,214 - $359,078	8,200 Added 8.91%	100,200 $3.24 Million
Q4 2023 Feb 09, 2024	SELL	$31.31 - $44.19 $760,833 - $1.07 Million	-24,300 Reduced 20.89%	92,000 $3.88 Million
Q3 2023 Nov 09, 2023	SELL	$18.55 - $39.96 $404,390 - $871,128	-21,800 Reduced 15.79%	116,300 $4.46 Million
Q2 2023 Aug 11, 2023	SELL	$14.2 - $23.75 $1.76 Million - $2.95 Million	-124,000 Reduced 47.31%	138,100 $2.62 Million
Q1 2023 May 10, 2023	BUY	$15.27 - $19.72 $4 Million - $5.17 Million	262,100 New	262,100 $4.07 Million

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hillsdale Investment Management Inc. with notifications on news.